TOP TEN perturbations for 39660_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39660_at
Selected probe(set): 210397_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39660_at (210397_at) across 6674 perturbations tested by GENEVESTIGATOR:
nephroblastoma study 2 / normal kidney tissue (adult)
Relative Expression (log2-ratio):-7.2313614Number of Samples:4 / 3
Experimental | nephroblastoma study 2 |
Tumor tissue samples from the kidney of patients with Wilms’ tumor. | |
Control | normal kidney tissue (adult) |
Normal adult kidney tissue samples. |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-6.712474Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
breast cancer study 40 (metastase; ovary) / ovarian tumor study 28 (clear cell adenocarcinoma)
Relative Expression (log2-ratio):-6.5511255Number of Samples:44 / 6
Experimental | breast cancer study 40 (metastase; ovary) |
Metastatic tumor tissue obtained from the ovary of female patients with primary breast cancer. | |
Control | ovarian tumor study 28 (clear cell adenocarcinoma) |
Primary tumor tissue sample obtained from the ovary of female patients with clear cell adenocarcinoma. |
ovarian tumor study 28 (carcinosarcoma) / ovarian tumor study 28 (clear cell adenocarcinoma)
Relative Expression (log2-ratio):-6.48771Number of Samples:2 / 6
Experimental | ovarian tumor study 28 (carcinosarcoma) |
Primary tumor tissue sample obtained from the ovary of female patients with carcinosarcoma. | |
Control | ovarian tumor study 28 (clear cell adenocarcinoma) |
Primary tumor tissue sample obtained from the ovary of female patients with clear cell adenocarcinoma. |
IFNa-2a study 1 / normal monocyte sample
Relative Expression (log2-ratio):5.5675764Number of Samples:7 / 7
Experimental | IFNa-2a study 1 |
Monocyte samples isolated from healthy donors and stimulated in vitro by 100 ng/ml IFNα2a in whole blood for 1.5 hour. Following stimulation, monocytes were depleted from granulocytes using CD15 MACS beads, and they were sorted from remaining peripheral blood leukocytes by CD14 labeling. | |
Control | normal monocyte sample |
Monocyte samples isolated from healthy subjects. Peripheral blood monocytes were isolated immediately after drawing blood by depletion from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocyte by CD14 labeling. |
expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)
Relative Expression (log2-ratio):-5.442581Number of Samples:3 / 4
Experimental | expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) |
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, sarcomatoid. | |
Control | expO kidney cancer study 1 (granular cell carcinoma; primary) |
Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma. |
ovarian tumor study 17 / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):5.437928Number of Samples:9 / 10
Experimental | ovarian tumor study 17 |
Human epithelial tumor cell samples from the ovary of patients with primary clear cell carcinoma. Samples were derived by laser capture microdissection (LCM). | |
Control | normal ovarian surface epithelial cell sample |
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from donors with non-cancerous, benign gynecological diseases. |
rheumatoid arthritis study 31 / IFNa-2a study 1
Relative Expression (log2-ratio):-5.3926735Number of Samples:4 / 7
Experimental | rheumatoid arthritis study 31 |
Monocyte samples isolated from patients with rheumatoid arthritis (RA). Monocytes from whole blood were depleted from granulocytes by CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocytes by CD14 labeling. Patients fulfilled the revised American College of Rheumatology criteria (ACR) for RA. | |
Control | IFNa-2a study 1 |
Monocyte samples isolated from healthy donors and stimulated in vitro by 100 ng/ml IFNα2a in whole blood for 1.5 hour. Following stimulation, monocytes were depleted from granulocytes using CD15 MACS beads, and they were sorted from remaining peripheral blood leukocytes by CD14 labeling. |
melanoma study 34 (metastatic) / melanoma study 34 (in situ)
Relative Expression (log2-ratio):-5.2522316Number of Samples:40 / 2
Experimental | melanoma study 34 (metastatic) |
Metastatic tumor tissue sample obtained from the patients with metastatic malignant melanoma of the skin. Metastatic samples composed of 22 macroscopic lymph node metastases, 16 subcutaneous metastases and 2 solid organ metastases (adrenal and brain). | |
Control | melanoma study 34 (in situ) |
Tumor tissue from the skin of patients with melanoma in situ. |
TGF-ß study 5 (late) / untreated A549 cell sample
Relative Expression (log2-ratio):-5.22091Number of Samples:3 / 3
Experimental | TGF-ß study 5 (late) |
Human A549 cells were treated with 5ng/ml porcine TGF-ß after serum-starving for 24h. Samples were taken 72 hours after TGF-ß treatment. | |
Control | untreated A549 cell sample |
A549 cells were grown for 24 hours. Samples were taken immediately before TGF-ß treatment. |